174 related articles for article (PubMed ID: 37633920)
1. The DDUP protein encoded by the DNA damage-induced CTBP1-DT lncRNA confers cisplatin resistance in ovarian cancer.
Ren L; Qing X; Wei J; Mo H; Liu Y; Zhi Y; Lu W; Zheng M; Zhang W; Chen Y; Zhang Y; Pan T; Zhong Q; Li R; Zhang X; Ruan X; Yu R; Li J
Cell Death Dis; 2023 Aug; 14(8):568. PubMed ID: 37633920
[TBL] [Abstract][Full Text] [Related]
2. LncRNA CTBP1-DT-encoded microprotein DDUP sustains DNA damage response signalling to trigger dual DNA repair mechanisms.
Yu R; Hu Y; Zhang S; Li X; Tang M; Yang M; Wu X; Li Z; Liao X; Xu Y; Li M; Chen S; Qian W; Gong LY; Song L; Li J
Nucleic Acids Res; 2022 Aug; 50(14):8060-8079. PubMed ID: 35849344
[TBL] [Abstract][Full Text] [Related]
3. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
Xiao Y; Lin FT; Lin WC
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33408251
[TBL] [Abstract][Full Text] [Related]
4. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
Nicholson HA; Sawers L; Clarke RG; Hiom KJ; Ferguson MJ; Smith G
Br J Cancer; 2022 Oct; 127(7):1340-1351. PubMed ID: 35778553
[TBL] [Abstract][Full Text] [Related]
6. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
8. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
9. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts.
Yunmbam MK; Guo Y; Miller MR; Yu JJ
Oncol Rep; 2004 Apr; 11(4):833-8. PubMed ID: 15010881
[TBL] [Abstract][Full Text] [Related]
12. NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.
Özeş AR; Miller DF; Özeş ON; Fang F; Liu Y; Matei D; Huang T; Nephew KP
Oncogene; 2016 Oct; 35(41):5350-5361. PubMed ID: 27041570
[TBL] [Abstract][Full Text] [Related]
13. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
14. NEDDylation antagonizes ubiquitination of proliferating cell nuclear antigen and regulates the recruitment of polymerase η in response to oxidative DNA damage.
Guan J; Yu S; Zheng X
Protein Cell; 2018 Apr; 9(4):365-379. PubMed ID: 28831681
[TBL] [Abstract][Full Text] [Related]
15. LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients.
Xu QF; Tang YX; Wang X
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4440-4447. PubMed ID: 30058681
[TBL] [Abstract][Full Text] [Related]
16. Replication protein A dynamically regulates monoubiquitination of proliferating cell nuclear antigen.
Hedglin M; Aitha M; Pedley A; Benkovic SJ
J Biol Chem; 2019 Mar; 294(13):5157-5168. PubMed ID: 30700555
[TBL] [Abstract][Full Text] [Related]
17. Rad18 regulates DNA polymerase kappa and is required for recovery from S-phase checkpoint-mediated arrest.
Bi X; Barkley LR; Slater DM; Tateishi S; Yamaizumi M; Ohmori H; Vaziri C
Mol Cell Biol; 2006 May; 26(9):3527-40. PubMed ID: 16611994
[TBL] [Abstract][Full Text] [Related]
18. The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.
Chang KE; Wei BR; Madigan JP; Hall MD; Simpson RM; Zhuang Z; Gottesman MM
Mol Cancer Ther; 2015 Jan; 14(1):90-100. PubMed ID: 25376608
[TBL] [Abstract][Full Text] [Related]
19. Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer.
Liu H; Deng S; Yao X; Liu Y; Qian L; Wang Y; Zhang T; Shan G; Chen L; Zhou Y
Oncogene; 2024 Mar; 43(10):714-728. PubMed ID: 38225339
[TBL] [Abstract][Full Text] [Related]
20. SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis.
Zhu Y; Yang L; Wang J; Li Y; Chen Y
J Gynecol Oncol; 2022 Nov; 33(6):e75. PubMed ID: 36245227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
